Sánchez VI, Peralta RJ

Language: Spanish
References: 18
Page: 73-81
PDF size: 318.85 Kb.

ABSTRACT

Introduction: T2DM is characterized by the presence of insulin resistance, a progressive dysfunction of β-cells with the loss of hormone secretion. It has been described that the molecular alterations in T2DM are often present even before the identification of fasting and 2-hr oral glucose tolerance test (OGTT) hyperglycemia. Quantification of protein fraction HbA1c% (affected in structure and/or functionality) has been of utmost importance, since its use is usually diagnostic, prognostic and for glycemic control over time, in addition, it has been considered as a biomarker of cardiovascular risk. However, it is unknown if other proteins could be relevant in the clinical application in these phenotypes. It has been suggested that the translation of the knowledge acquired by proteomic studies may be of great help for the identification of target proteins in prevention, diagnosis, approach and/or prognosis of vulnerable patients to T2DM, even before the presence of alterations in glycemic concentrations and their complications. Objective: The present article intends to explain the importance of the study of proteomics and its potential helpfulness in type 2 diabetes mellitus (T2DM). Conclusions: In the present review, we analyzed different proteins derived from proteomic studies that could be of future importance in the approach to T2DM.

REFERENCES

1. Rojo-Martínez G, Valdés-Hernández S. Epidemiología de la diabetes mellitus tipo 2. En: Tratado de diabetes mellitus. España: Editorial Médica Panamericana; 2017, 15-22.

2. Vendrell-Ortega J. Fernandez-Veledo S. Fisiopatología de la diabetes mellitus tipo 2. En: Tratado de diabetes mellitus. España: Editorial Médica Panamericana; 2017. 35-46.

3. Riddle Matthew. Classification and diagnosis of diabetes. Diabetes care the journal of clinical and applied research and education. Edit American Diabetes Association. 2021;44:40-52.

4. Kraniotou, C. Predictive biomarkers for type 2 of diabetes mellitus: Bridging the gap between systems research and personalized medicine. Journal of Proteomics., Edit Elsevier. 2018.

5. Fernández-Llama P. Aportaciones de la proteómica al estudio de las enfermedades cardiovasculares. Hipertens Riesgo Vasc. Edit. Doyma. 2011;28:16-19.

6. Jiménez-Flores L, Flores-Pérez C, Mares-Álvarez P, Macías-Cervantes H, Ramírez-Emiliano J, Pérez-Vázquez V. Aportaciones de la proteómica en el estudio de la diabetes. Gaceta Médica de México. 2014;150:88-94.

7. López-Villar E, Martos-Moreno G, Chowen J, Okada S, Kopchick J, Argente J. A proteomic Approach to obesity and type 2 diabetes. J Cell Mol Med. 2015;19:1455-1470.

8. Metz TO, Jacobs JM, Gritsenko MA et al. Characterization of the human pancreatic islet proteome by two-dimensional LC/MS/MS. J Proteome Res. 2006;5(12):3345-3354.

9. Qiu L, List EO, Kopchick JJ. Differentially expressed proteins in the pancreas of diet-induced diabetic mice. Mol Cell Proteomics. 2005;4(9):1311-1318.

10. Gómez-Zorita S, Urdampilleta A. El GLUT4: efectos de la actividad física y aspectos nutricionales en los mecanismos de captación de glucosa y sus aplicaciones en la diabetes tipo 2. Av Diabetol. 2012;28:19-26.

11. Barres R, Zierath J. DNA methylation in metabolic disorders, Am J Clin Nutr. 2011;93:897S-900S.

12. Kaufman R, Scheuner D, Schroder M. The unfolded protein response in nutrient sensing and differentiation, Nat Rev Mol Cell Biol. 2001;3:41-421.

13. Mullen E, O'Reilly E, Ohlendieck K. Skeletal muscle tissue from the Goto-Kakizaki rat model of type-2 diabetes exhibits increased levels of the small heat shock protein Hsp27. Mol Med Rep. 2011;4(2):229-236.

14. Hittel DS, Hathout Y, Hoffman EP, Houmard JA. Proteome analysis of skeletal muscle from obese and morbidly obese women. Diabetes. 2005;54(5):1283-1288.

15. Sun HD, Ru YW, Zhang DJ et al. Proteomic analysis of glutathione S-transferase isoforms in mouse liver mitochondria. World J Gastroenterol. 2012;18(26):3435-3442.

16. Nandi A, Kitamura Y, Kahn CR, Accili D. Mouse models of insulin resistance. Physiol Rev. 2004;84:623-647.

17. Tozzo E, Ponticiello R, Swartz J et al. The dual peroxisome proliferator activated receptor alpha/gamma activator muraglitazar prevents the natural progression of diabetes in db/db mice. J Pharmacol Exp Ther. 2007;321:107.

18. Beijer K, Nowak C, Sundstrom J. In search of causal pathways in diabetes: a study using proteomics and genotyping data from a cross-sectional study. Diabetologia. 2019;62(11):1998-2006.